Exchange: NASDAQ·Updated 01:13 PM EDT
IMRX logo

IMRX Immuneering Corp

$4.90
$0.14
(2.78%)
Today
Reported EarningsAug 6
Mkt Cap$326.07M
Vol548,083.00

About IMRX

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
53

Neutral Sentiment

How do you feel about IMRX?

Advertisement|Remove ads.